R1	Has_value Arg1:T2 Arg2:T1	
*	OR T3 T4
R2	Has_qualifier Arg1:T3 Arg2:T5	
R3	Has_value Arg1:T7 Arg2:T8	
R4	Has_index Arg1:T9 Arg2:T10	
R5	Has_index Arg1:T11 Arg2:T12	
R6	Has_temporal Arg1:T3 Arg2:T11	
R7	Has_temporal Arg1:T3 Arg2:T9	
*	OR T13 T14
R8	Subsumes Arg1:T18 Arg2:T19	
R9	Has_value Arg1:T17 Arg2:T18	
R10	AND Arg1:T13 Arg2:T17	
R11	AND Arg1:T13 Arg2:T15	
R12	Has_index Arg1:T20 Arg2:T21	
R13	AND Arg1:T23 Arg2:T22	
R14	AND Arg1:T24 Arg2:T23	
R15	Has_index Arg1:T25 Arg2:T26	
R16	Has_index Arg1:T27 Arg2:T28	
*	OR T25 T27
R17	Has_temporal Arg1:T23 Arg2:T25	
T1	Value 13 30	18 years or older
T2	Person 8 12	aged
T3	Condition 73 89	active proctitis
T4	Condition 93 117	distal proctosigmoiditis
T5	Qualifier 56 72	mild to moderate
T7	Measurement 119 129	MAYO score
T8	Value 130 142	≥ 3 and ≤ 10
T9	Temporal 199 237	within 6 months before study inclusion
T10	Reference_point 222 237	study inclusion
T11	Temporal 144 156	at inclusion
T12	Reference_point 147 156	inclusion
T13	Condition 276 292	active proctitis
T14	Condition 296 320	distal proctosigmoiditis
T15	Procedure 265 275	endoscopic
T17	Measurement 322 345	Montreal classification
T18	Value 346 354	E1 or E2
T19	Qualifier 369 421	involvement not exceeding 25 cm from the anal margin
T20	Temporal 423 461	within 6 months before study inclusion
T21	Reference_point 446 461	study inclusion
T22	Drug 500 507	Pentasa
T23	Procedure 464 473	Treatment
T24	Condition 489 494	flare
T25	Temporal 609 635	during the inclusion visit
T26	Reference_point 620 635	inclusion visit
T27	Temporal 639 681	during the week before the inclusion visit
T28	Reference_point 646 681	the week before the inclusion visit
T30	Non-query-able 684 861	Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form
